Drug intelligence / Profile preview

polyethylene glycol + lubiprostone

Development stage
Unknown
Lead developer
Mallinckrodt
Modality
Small Molecules
Administration
Oral
01

Overview

Polyethylene glycol + lubiprostone is a combination therapy used primarily for bowel preparation before colonoscopy and for the management of constipation, particularly in patients with chronic idiopathic constipation or those who are difficult to prep, such as individuals with diabetes. Polyethylene glycol (PEG) acts as an osmotic laxative by retaining water in the colon, thereby softening stools and promoting bowel movements. Lubiprostone is a prostaglandin E1 derivative that activates chloride channel protein 2 (ClC-2) on gastrointestinal epithelial cells, increasing chloride-rich fluid secretion into the intestinal lumen, which further softens stool and enhances motility. The combination has been studied to determine if it improves bowel cleansing efficacy compared to PEG alone; some studies suggest modest improvement in certain populations (e.g., diabetics), while others show no significant additional benefit over PEG alone[1][2][4]. Both agents are approved individually for constipation-related indications.

Brand names
Amitiza
Other names
polyethylene glycol electrolyte lavage solution + lubiprostonePEG-electrolyte solution + lubiprostone
02

Targets

CLCN2 (Chloride channel protein CIC-2)

Beyond the preview

Go deeper on polyethylene glycol + lubiprostone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyethylene glycol + lubiprostone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call